

























































published: 04 September 2014
doi: 10.3389/fonc.2014.00242
Clinical applications of circulating tumor cells in lung
cancer patients by CellSearch system
AnnaTruini*, Angela Alama, Maria Giovanna Dal Bello, Simona Coco, IreneVanni , Erika Rijavec,
Carlo Genova, Giulia Barletta, Federica Biello and Francesco Grossi
Lung Cancer Unit, IRCCS AOU San Martino-IST, Genoa, Italy
Edited by:
Stephen V. Liu, Georgetown
University, USA
Reviewed by:
Janaki Deepak, University of
Maryland School of Medicine, USA
Vinesh Puliyappadamba, University of
Alabama, USA
*Correspondence:
AnnaTruini , Lung Cancer Unit, IRCCS
AOU San Martino-IST, L.go R. Benzi
10, Genoa 16132, Italy
e-mail: anna.truini@hsanmartino.it
Circulating tumor cells (CTCs) are cells spread from the primary tumor into the bloodstream
that might represent an important biomarker in lung cancer.The prognosis of patients diag-
nosed with lung cancer is generally poor mainly due to late diagnosis. Recent evidences
have reported that tumor aggressiveness is associated with the presence of CTCs in the
blood stream; therefore, several studies have focused their attention on CTC isolation, char-
acterization, and clinical significance. So far, the CellSearch® system is the only approach
approved by FDA for metastatic breast, prostate, and colorectal cancer intended to detect
CTCs of epithelial origin in whole blood and to assess prognosis. To date, no specific bio-
markers have been validated in lung cancer and the identification of novel tumor markers
such as CTCs might highly contribute to lung cancer prognosis and management. In the
present review, the significance of CTC detection in lung cancer is examined through the
analysis of the published studies in both non-small cell and small cell lung cancers; addi-
tionally the prognostic and the clinical role of CTC enumeration in treatment monitoring
will be reported and discussed.
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CTC AND LUNG CANCER
Circulating tumor cells (CTCs) are widely recognized to be shed
into the peripheral blood from solid tumor playing an important
role in the development of metastasis (1, 2). Recent improvements
in technical approaches able to identify CTCs from whole blood
withdrawal have demonstrated the potential value of CTC detec-
tion as a liquid biopsy especially in those tumors where tissue
accessibility is often challenging as in lung cancer (3, 4). Lung can-
cer is the first cause of cancer related death worldwide and both
histotypes: small cell lung cancer (SCLC) and non-small cell lung
cancer (NSCLC) have poor survival rate.
Although SCLC is more responsive to chemotherapy and radio-
therapy than other types of lung cancers, it is frequently dissem-
inated by the time of diagnosis and complete tumor response
is generally difficult to achieve (median survival ranges from 7
to 12 months) (5). Similarly, the overall survival (OS) of NSCLC
patients is generally poor (median survival of 12–14 months) and
despite significant advances in the NSCLC management the 5-
years OS remains unsatisfied (~15%) primarily attributable to late
diagnosis when surgery is no longer possible (6).
The current standard of care for both advanced SCLC
and NSCLC patients consists in platinum-based combination
chemotherapy (7, 8) but the identification of activating muta-
tions in the epidermal growth factor receptor (EGFR) gene and
the presence of an anaplastic lymphoma kinase (ALK ) rearrange-
ment in sub-groups of NSCLC have improved the clinical out-
come of these patients by treatment with specific tyrosine kinase
inhibitors (i.e., gefitinib, erlotinib, afatinib) and ALK inhibitors
(crizotinib, ceritinib), compared with conventional chemotherapy
alone (9–12). Additionally, the possibility of performing analyses
by means of CTCs, such as genotyping and molecular charac-
terization, has opened new important perspectives for lung can-
cer patients by tailoring therapeutic strategies and monitoring
treatment efficacy (13).
To date, the CellSearch® (Veridex LLC, Raritan, NJ, USA) sys-
tem is the only technique, approved by the US Food and Drug
Administration (FDA), for baseline CTC enumeration as an aid to
prognosis and treatment efficacy in breast, colorectal and prostate
cancers (14–16). Although the CellSearch procedure needs to be
further validated in lung cancer, a number of studies already
reported significant data about the role of CTCs in this disease.
The CellSearch system is a semi-automated methodology able
to detect and enumerate CTCs. Analysis is carried out in 7.5 ml
of whole blood using three different antibodies: the epithelial
cell adhesion molecule (EpCAM), cytokeratin (CK), and CD45.
Peripheral blood is mixed with magnetic iron nanoparticles coated
with anti-EpCAM antibody to confer magnetic properties to
the epithelial cells. In order to detect these epithelial cells and
exclude the presence of leukocytes (CD45+), anti-CK and anti-
CD45 fluorescent antibodies are respectively used. In addition
cell nuclei are fluorescently labeled with the DAPI nuclear dye
(4′,6-diamidino-2-phenylindole) to allow microscopic identifi-
cation of the relevant cell fraction. A strong magnetic field is
then applied to separate the cell population that can be detected
and counted by digital fluorescent microscopy. The identifica-
tion of CTCs is based on specific features: CK+, nuclear stain-
ing by DAPI and lack of CD45 expression (Figure 1). However,
this system is unable to detect the CTCs, with fibroblastic-like
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FIGURE 1 | Schematic diagram of CellSearch system technology. PB,
peripheral blood; CTC, circulating tumor cell; EpCAM, epithelial cell
adhesion molecule; CK–PE, cytokeratins–phytoerythrin; CD45-APC, cluster
of differentiation 45-allophycocyanin; N-DAPI, nucleus stained with DAPI.
phenotype (EpCAM-negative), that have been observed during
disease progression and metastasis.
While several methodologies have been described to isolate the
CTCs in lung cancer, the current review will focus on the most
significant data in SCLC and NSCLC patients obtained by the
CellSearch system.
One of the first study dates back to 2007 and reported the
changes in CTC count before and after surgery in nine male
patients who underwent surgery for NSCLC. The results showed
that one patient and three patients reported CTCs prior to surgery
and immediately after the operation, respectively and no CTCs
were detected in any of these patients 10 days after surgery. Addi-
tionally no recurrence was reported after a median follow-up
of 14 months in any of the patients, in concordance with CTC
count (17).
Starting from the above-mentioned pioneering study in this
field several investigations have focused on CTCs to explore their
role in more detail (Table 1).
ROLE OF CTC IN DIAGNOSIS AND PROGNOSIS
To date, several studies have shown that, in the absence of tumor
biopsies, the detection of CTCs in the peripheral blood of patients
with lung cancer may hold great promise as a surrogate tissue
in defining prognosis and predicting efficacy of chemotherapy
treatment (3, 4, 18).
The majority of patients with a pulmonary nodule undergo
fine needle biopsy and are diagnosed by cytological examination
only. However, extensive immune-cytochemical analyses are rarely
feasible due to the small amount of available material, leading
to misdiagnosis. Bevilacqua and colleagues performed analyses
on peripheral blood sample using the CellSearch system in a
patient diagnosed with low-grade neuroendocrine tumor follow-
ing fine needle biopsy. EpCAM and CK positive expressions could
not correlate with the neuroendocrine tumor diagnosis since no
evidence of epithelial markers was found in this malignancy. Fur-
ther immunophenotypic characterization on the biological mate-
rial derived from a biopsy of a liver metastasis disclosed diffuse
cell positivity for EpCAM and CK pool: these observations were
consistent with a diagnosis of SCLC (19). Although this study
underlined the importance of CTC in diagnosis of critic samples,
the majority of the reported articles focused their attention on the
prognostic role of CTCs.
A prospective study evaluating CTCs in 150 patients with
a suspicious or a diagnosis of primary lung cancer using the
CellSearch system was reported by Tanaka et al. The authors inves-
tigated the diagnostic role of CTCs by discriminating lung cancer
from non-malignant disease. However, although CTC count was
higher in lung cancer patients compared to patients with non-
malignant disease, the receiver operating characteristic (ROC)
curve did not disclose a good discrimination between lung can-
cer patients and healthy controls (CTCs were identified in 30.6
and 12%, respectively). Nevertheless, this study reported the sig-
nificant role of CTCs in predicting distant metastasis (AUC-ROC,
0.783; p< 0.001) since CTC count was higher in SCLC compared
to NSCLC and was able to well differentiate stage I from stage IV
tumors (20).
Another article reporting the prognostic role of CTC has been
published by Hou and colleagues who focused on the expression
and clinical significance of CTCs in 50 patients affected by SCLC
who received standard chemotherapy treatment (21). Baseline
CTCs ≥2 cells were found in 86% of patients with a median CTC
number of 28. The median survival for patients with CTC num-
ber>300 was 134 days compared with about 400 days for patients
with low CTC number (p< 0.005); higher CTC number was sig-
nificantly associated with shorter survival in the univariate analysis
(p= 0.01) underlining the role of CTC in prognosis. In addition,
in the 24 samples available after chemotherapy, the CTC number
decreased following treatment being the CTCs detectable in 60%
of patients only compared with 86% at baseline. These results
provided a rationale to include CTC analysis in SCLC patients.
More recently, a study by Naito et al. showed the prospective
assessment of the optimal CTC-cut-off, determined by CellSearch,
to predict the OS in 51 patients with SCLC treated with chemother-
apy or chemo-radiotherapy. Two or more CTCs were identi-
fied in 68.6, 26.5, and 67.6% of the patients at baseline, post-
chemotherapy, and at relapse, respectively. The optimal cut-off of
>8 CTCs per 7.5 ml of blood was recognized as significantly pre-
dictive of the OS and the CTC presence at post-treatment and at
relapse strongly correlated with worse outcome (22).
Interestingly, an important study able to demonstrate that
CTCs in SCLC represent a better predictor of survival than dis-
ease stage and tumor response, assessed by computed tomography
(CT), was reported by Hiltermann and colleagues in 2012. Blood
samples were obtained from 59 SCLC patients and CTCs were
measured before, after one cycle, and at the end of chemotherapy.
Lower numbers of CTCs at baseline were detected in patients with
localized SCLC (median= 6) respect to patients with metasta-
tic disease (median= 63). Additionally, a better clinical outcome
was correlated with lack of measurable CTCs (p≤ 0.001). CTCs
decreased after the first cycle of chemotherapy and the multi-
variate Cox regression analysis revealed that CTC count was a
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Table 1 | Summary of relevant results from CTC studies in lung cancer by CellSearch.
Reference Sample number Histotype Results
Sawabata et al. (17) 9 NSCLC CTC-positive in 4/9 patients. No recurrence after surgery
Bevilacqua et al. (19) 5 SCLC CTC have a role in SCLC patients diagnosis
Tanaka et al. (20) 150 NSCLC and SCLC CTC well differentiate stage I from stage IV tumors
Hou et al. (21) 50 SCLC CTCs≥2 in 86%. Higher CTC number→ shorter OS. CTC-positive decreased after
CT (60%)
Naito et al. (22) 51 SCLC CTCs detected in 68.6, 26.5, and 67.6% at B, post-CT, and R, respectively.
CTCs>8→worse OS
Hiltermann et al. (23) 59 SCLC Median CTCs at B=6 and 63 in localized and metastatic disease, respectively. CTCs
decrease after CT→ strong predictor of OS
Normanno et al. (24) 60 SCLC CTCs identified in 90% at B and associated to involved organs. CTC reduction higher
than 89% after CT→better OS
Hou et al. (25) 97 SCLC CTCs present in 85%. CTCs≥50 at B→worse OS. Failure of CTC to decrease <50
after CT→worse prognosis
Krebs et al. (26) 101 NSCLC CTC number at B higher in stage IV than stage III (60 and 27, respectively).CTCs
number→prognostic factor for PFS and predictor of OS after first cycle of CT
Hirose et al. (27) 33 NSCLC CTCs positive in 36.4 and 15.2% had five or more CTCs before CT. Positive CTCs
patients→progressive disease
Punoose et al. (28) 41 NSCLC CTCs identified in 78% at B. CTC decrease during CT→ longer PFS
Muinelo-Romay et al. (29) 43 NSCLC CTCs detected in 41.9%. CTCs≥5→ shorter PFS and OS. CTC decrease after
second cycle of CT→higher response and better PFS and OS
Isobe et al. (30) 24 NSCLC CTCs detected in 33.3%. EGFR mutations in cfDNA: 25%. EGFR mutation rate in
cfDNA higher when CTCs≥2
Swennenhuis et al. (31) 10 NSCLC and SCLC DNA isolation and sequencing from a single CTC
NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; OS, overall survival; PFS, progression-free survival; B, baseline; CT, chemotherapy; R, relapse;
cfDNA, circulating free DNA.
stronger predictor for OS (p= 0.004) than disease stage and CT
evaluation. Although CTC enumeration was not associated with
tumor response after four cycles of chemotherapy, patients with
low baseline CTC numbers lived longer than those with higher
CTCs (23).
Recently, a study by Normanno and colleagues assessed the
prognostic value of CTCs in 60 patients with extensive SCLC.
Using the CellSearch system, the CTCs were enumerated and ana-
lyzed separately at baseline, after one cycle of chemotherapy and
as a change between the two counts. CTCs were identified in 90%
of the patients and the count was significantly associated with the
number of organs involved by disease. CTC determination after
one cycle of chemotherapy was not always feasible and the analyses
between the two counts were performed in 40 patients only. Inter-
estingly, a CTC reduction higher than 89% after chemotherapy
was significantly associated with a better outcome. The authors
concluded that an early decline of CTC number after the first
chemotherapy cycle was significantly more useful than baseline
CTC count in estimating prognosis in this sub-group of patients
with advanced SCLC (24).
The prognostic value of CTC enumeration was further demon-
strated by Hou and colleagues in 97 patients affected by SCLC
receiving chemotherapy. They investigated the role of CTCs
and CTC cluster, named circulating tumor microemboli (CTM).
CTCs were detected in 85% of the patients at baseline (prior
to any chemotherapy) whereas CTM were detected in 32% of
the patients presenting CTCs. Categorizing patients into favor-
able and unfavorable group, based on CTC number, the authors
reported a significantly different outcome in term of progression-
free survival (PFS: 4.6 and 8.8 months, respectively), and OS (5.4
and 11.5 months, respectively). These results demonstrated that
baseline CTC presence was an independent prognostic factor
(p< 0.0001). CTC counts was the most significant variable in a
multivariate model and failure of CTC number to decrease to less
than 50 after one cycle of chemotherapy was associated with worse
prognosis. This study demonstrated the presence of CTM in SCLC
and that CTCs and CTM are associated with worse prognosis in
SCLC (25).
In 2011, Krebs and colleagues reported the prognostic role of
CTCs also in NSCLC. In a single-center prospective study, 101
chemo-naïve stage III–IV NSCLC patients were enrolled and eval-
uated before and after one cycle of chemotherapy. Twenty-one per
cent of the patients had a CTC count at baseline greater than two
cells and CTC number was much higher in stage IV patients com-
pared to stage III NSCLC patients, reporting a mean of 60 and 27
CTCs, respectively. The univariate analysis showed a significantly
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better PFS and OS (p< 0.001) in patients with fewer CTCs. Fur-
thermore, in the multivariate analysis, the CTC number remained
an independent prognostic factor for PFS and was the strongest
predictor of OS also in the sub-group of patients whose CTC
analysis was feasible before and after one cycle of chemotherapy
(26).
CLINICAL SIGNIFICANCE OF CTC TO TREATMENT RESPONSE
Besides the significance of the CTCs as diagnostic and prognostic
indicators, an important goal for clinical application is repre-
sented by the early indication of patient response to conventional
treatment.
Hirose and colleagues prospectively evaluated the relation-
ship between CTC count and chemotherapy treatment in 33
metastatic NSCLC patients further treated with gemcitabine and
carboplatin. This study revealed no differences in chemother-
apy response between CTC-positive and CTC-negative patients
whereas PFS was significantly higher in CTC-positive compared to
CTC-negative patients revealing that CTCs might be an important
predictive factor for the effectiveness of chemotherapy treatment
in advanced NSCLC patients (27).
A multicenter phase II study, involving 41 advanced NSCLC
patients treated with erlotinib and pertuzumab, investigated the
predictive significance of CTC number variation during treatment
in relation to response (evaluated with positron emission tomog-
raphy and CT-scan) and clinical outcome. CTCs were identified
at baseline in 78% of the patients, and a statistically significant
correlation between high CTC count and treatment response was
reported (p= 0.009). Additionally, decreased CTC count during
treatment correlated with longer PFS (p= 0.05). These data sug-
gest that CTC enumeration during therapy might help defining
clinical response and monitoring treatment efficacy (28).
In another study, the blood samples of 43 advanced NSCLC
patients were analyzed before the first, second, and fifth cycles
of platinum-based chemotherapy. Morphologically intact CTCs
were detected in 41.9% of the patients and patients with CTCs≥5
presented a significantly shorter median PFS and OS (4.1 and
4.6 months, respectively) compared to patients with <5 CTCs
(median PFS and OS of 7.6 and 10.7 months, respectively). A
marked decrease of CTCs after the second cycle of chemother-
apy correlated with an overall response rate and a better OS
and PFS supporting the predictive role of CTCs as indicator of
chemotherapy response (29).
FUTURE PERSPECTIVES
Alongside enumeration, the importance of CTC detection also
relies on the possibility of performing molecular investigations in
cluster or single CTCs to be correlated with data from the primary
tumor tissue or circulating free DNA (cfDNA).
Isobe and colleagues evaluated the blood content of CTCs to
determine a correlation between CTCs and cfDNA in advanced
NSCLC patients after acquisition of resistance to EGFR tyrosine
kinase inhibitors. CTCs were detected in 33.3% of the patients
whereas EGFR mutations were reported in 25% of cases using the
Cycleave real-time PCR assay. The EGFR mutation rate in cfDNA
was significantly higher in patients with more than two CTCs
per 7.5 ml of blood compared to patients reporting less than two
CTCs, leading to hypothesize that the presence of EGFR mutation
in cfDNA correlated with a higher number of CTCs in the blood
and a more aggressive disease (30).
Based on the increased importance of CTCs, very recently
Swennenhuis and colleagues evaluated efficiency and quality of
DNA isolation from a single CTC in order to characterize the
mutational landscape of CTCs. Using the CellSearch system fol-
lowed by fluorescence-activated cell sorting (FACS), a single CTC
was sequenced using whole genome amplification (WGA) report-
ing for the first time that 55% of the exome was successfully
sequenced at 20× depth calling 72% of the variants (31).
CONCLUSION
To date, the CellSearch system is the only method approved by
FDA to detect and enumerate the CTCs in breast, colorectal, and
prostate cancers but a number of studies in SCLC and NSCLC
have shown that CTCs might represent an important diagnostic
and prognostic biomarker in lung cancer as well. Additionally, an
important goal for clinical application involves the early indica-
tion of patient’s response to conventional treatment by analyzing
CTC variation.
Blood samples can be obtained on a serial basis during treat-
ment allowing the identification of early chemotherapy resistance
profiles in real time. Indeed variations in CTC levels during treat-
ment may reveal changes in disease status that might influence
therapeutic decisions in the clinical setting.
Although the timing of CTC detection and imaging evalua-
tions during treatment, reported in various studies, are rather
heterogeneous, additional data about CTC enumeration associ-
ated with standard imaging techniques, in determining diagnosis
and prognosis of lung cancer, need to be warranted.
The feasibility to carry out molecular characterization of CTCs
using innovative sequencing technologies may additionally pro-
vide more specific and informative mutational landscape of the
cells involved in distant metastasis and recognize early recurrence
or chemotherapy resistance in lung cancer patients.
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